From cells to purified capsids: How to develop a scalable rAAV process

Cell & Gene Therapy Insights 2022; 8(3), 611–619

DOI: 10.18609/cgti.2022.094

Published: 16 June 2022
Åsa Hagner McWhirter

Adeno-associated viral (AAV) vectors are widely used for gene therapy, with multiple serotypes and several different synthetic capsid variants targeting different tissues. The number of AAVs in clinical trials has increased over recent years and the serotypes primarily used have changed, from AAV1 and AAV2 initially to AAV8 and AAV9 today.